LEXINGTON, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced that Dr. Garo Armen, Chairman and CEO of Agenus and Dr.

Data to be Presented in Heavily Pretreated MSS-CRC Speed and Innovation Core to Development Strategy Reduction of 20% in 2022 Operating Costs LEXINGTON, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed

Botensilimab data to be presented and Phase 2 trials to launch. AGEN1571 (ILT2) clinical trials to commence and data presented at AACR. AGEN2373 progressing in the clinic and Gilead milestone payment received. LEXINGTON, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Agenus Inc.

Conference Call on Tuesday, May 10, 2022 at 8:30 a.m. ET LEXINGTON, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and

First data presentation on AGEN1571 shows strong adaptive and innate immune responses Preclinical data indicate superior performance to the only clinical-stage competitor Monotherapy activity and broad combination potential Investigational New Drug (IND) application cleared; clinical trial to

LEXINGTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate immune response to cancers and infections, today announced receipt of a $5M clinical milestone payment for AGEN2373

The parties have entered into a collaboration agreement to develop Targovax´s TG mutant KRAS cancer vaccines in combination with Agenus´s QS-21 STIMULON adjuvant technology The agreement may be extended into an exclusive commercial partnership for KRAS vaccination if the combination proves

Botensilimab (Fc-enhanced) is the first anti-CTLA-4 antibody to demonstrate clinical responses across 9 cold, treatment-resistant cancers; Phase II studies planned in melanoma, MSS-colorectal, and pancreatic cancers AGEN1571, a novel program targeting tumor-associated macrophages, is entering

Conference Call on Tuesday, March 1, 2022 at 8:30 a.m. ET LEXINGTON, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and

LEXINGTON, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that management will participate in the

Objective response rate (ORR) of 32.8% in PD-L1-positive patients and 25.6% in all patients regardless of PD-L1 status Both ORRs and durability of responses are higher than what has been demonstrated with approved therapies for these patients Median duration of response (mDoR) not yet reached after

LEXINGTON, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr.

Seventeen objective responses reported across nine cancers Evidence of monotherapy activity, with four cases of confirmed objective response Objective responses noted in treatment refractory, poorly immunogenic tumors including microsatellite stable (MSS) colorectal cancer, ovarian cancer, MSS

Clinical results presented at SITC show that AGEN1181, as a monotherapy and in combination with balstilimab, shows durable responses in 9 cancer types, including patients whose cancers have recurred following PD-1 therapy Agenus will commence Phase 2/3 trials of AGEN1181 and balstilimab in

LEXINGTON, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr.

LEXINGTON, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr.

Conference Call on Tuesday, November 9, 2021, at 8:30 a.m. ET LEXINGTON, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to

Company voluntarily withdraws BLA at FDA’s recommendation following full approval of pembrolizumab, which came four months earlier than FDA goal date Balstilimab achieved trial endpoints with 20% response rates in PD-L1 positive patients, versus 14% reported in pembrolizumab’s label; Agenus

LEXINGTON, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it has triggered

LEXINGTON, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Agenus Inc . (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced acceptance of its

Objective response rate of 33% and median duration of response not reached with 19.4 months median follow-up in PD-L1+ tumors; expands benefit of anti-PD-1 alone Improved responses seen across all histology subgroups including populations of patients unresponsive to other therapies Dr.

Development of saponin molecules designed to provide high-efficacy and long-lasting protection for pandemic vaccines LEXINGTON, Mass. and BOSTON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies,

LEXINGTON, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Jennifer Buell,

Objective response rate of 20% and median duration of response not reached with 14.6 month median follow-up in PD-L1+ tumors Responses seen across all histology subgroups including populations of patients unresponsive to other therapies LEXINGTON, Mass., Aug.

$200M received from BMS for anti-TIGIT bispecific antibody collaboration FDA cleared IND for AGEN1777 clinical enrollment AGEN1181 rapidly advancing in the clinic; data to be presented in 2H 2021 Cell therapy subsidiary MiNK Therapeutics filed confidential S-1 for planned IPO FDA accepted